Thermidas: A Breakthrough in Non-Invasive Skin Temperature Measurement

By HEOR Staff Writer

August 21, 2023

FinCCHTA, the Finnish Coordinating Centre for Health Technology Assessment, has recommended the use of Thermidas, a non-invasive thermal imaging system, to support diagnostics and monitor treatment. The system, which includes imaging analysis and reporting software, is particularly useful for measuring skin surface temperature changes.

Thermidas has been shown to be effective in monitoring temperature differences, indicating changes in the circulatory index, subclinical infections, the severity of vascular disease, and specific complications of Charcot neuro-osteoarthropathy. It has also been found to be a reliable and reproducible method for measuring temperature across areas, compared to traditional point-like temperature measurements in healthy adults.

The system has been particularly beneficial in the monitoring of diabetic foot ulcers and rheumatoid arthritis. A study demonstrated that infrared thermal imaging was able to detect temperature differences in the feet of a group of patients at high risk due to diabetes. Another cross-sectional study showed that combined thermal and ultrasound imaging provides better information about the area under examination than either imaging method used alone in assessing arthritis in rheumatoid arthritis cases.

The Thermidas system is recommended for use until April 2026. The manufacturer has provided evidence of theoretical cost savings, particularly in the monitoring of diabetic podiatric conditions and inflammatory rheumatoid arthritis, as well as in support of diagnostics. The purchase price of the system includes deployment training, with post-acquisition product and maintenance support subject to a fee. 

Reference url

Recent Posts

medtech market access strategy
Prioritizing a Comprehensive Medtech Market Access Strategy Through Stakeholder Engagement

By João L. Carapinha

June 9, 2026

An effective medtech market access strategy must begin at the concept stage by simultaneously addressing patient needs, clinical workflows, regulatory requirements, and payer expectations rather than defaulting to FDA clearance as the sole priority. Startups that ignore this broader view risk bui...
HIV Weekly Treatment Options
Potential for Advancements in HIV Weekly Treatment Options

By João L. Carapinha

June 9, 2026

HIV Weekly Treatment Options took a major step forward as Gilead and Merck reported that their investigational once-weekly combination of islatravir and lenacapavir successfully met the primary endpoint in two Phase 3 trials. The oral regimen maintained viral suppression in adults already control...
Tovorafenib clinical assessment
Tovorafenib Clinical Assessment Outcomes and Methodological Challenges

By João L. Carapinha

June 9, 2026

The Tovorafenib clinical assessment conducted under the EU Joint Clinical Assessment process has exposed critical shortcomings in the evidence base for treating BRAF-altered pediatric low-grade glioma. Despite the therapy’s potential, reviewers concluded that robust comparative data is absent for...